Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial

Summary: The tyrosine kinase inhibitor erlotinib improves the outcomes of patients with advanced non-small-cell lung carcinoma (NSCLC) harbouring epidermal growth factor receptor (EGFR) mutations. The coexistence of the T790M resistance mutation with another EGFR mutation in treatment-naive patient...

Full description

Bibliographic Details

Main Authors:	Rosell, Rafael (Author) , Thomas, Michael (Author)
Format:	Article (Journal)
Language:	English
Published:	April 2017
In:	The lancet. Respiratory medicine Year: 2017, Volume: 5, Issue: 5, Pages: 435-444
ISSN:	2213-2619
DOI:	10.1016/S2213-2600(17)30129-7
Online Access:	Verlag, Volltext: http://dx.doi.org/10.1016/S2213-2600(17)30129-7 Verlag, Volltext: http://www.thelancet.com/journals/lanres/article/PIIS2213-2600(17)30129-7/abstract
Author Notes:	Prof Rafael Rosell, MD, Prof Urania Dafni, ScD, Enriqueta Felip, MD, Alessandra Curioni-Fontecedro, MD, Oliver Gautschi, MD, Solange Peters, MD, Bartomeu Massutí, MD, Ramon Palmero, MD, Santiago Ponce Aix, MD, Enric Carcereny, MD, Martin Früh, MD, Miklos Pless, MD, Sanjay Popat, FRCP, Athanasios Kotsakis, MD, Sinead Cuffe, MD, Paolo Bidoli, MD, Adolfo Favaretto, MD, Patrizia Froesch, MD, Noemí Reguart, MD, Javier Puente, MD, Linda Coate, MD, Prof Fabrice Barlesi, MD, Daniel Rauch, MD, Prof Michael Thomas, MD, Carlos Camps, MD, Jose Gómez-Codina, MD, Margarita Majem, MD, Rut Porta, MD, Riyaz Shah, FRCP, Emer Hanrahan, MRCPI, Roswitha Kammler, BA, Barbara Ruepp, PharmD, Manuela Rabaglio, MD, Marie Kassapian, MSc, Niki Karachaliou, MD, Rachel Tam, BSc, David S Shames, PhD, Miguel A Molina-Vila, PhD, Dr Rolf A Stahel for the BELIEF collaborative group